HAHenrik Andersson

Henrik Andersson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Henrik Andersson has a total of 120 co-authors. Here are the top co-authors by number of shared publications:

  • Michelle S. Chew

    Perioperative Medicine and Intensive Care, Karolinska University Hospital Huddinge and Division of Anesthesiology and Intensive Care CLINTEC, Karolinska Institute, Stockholm, Sweden

    6 shared publications
  • Anders Sjöstedt

    Department of Clinical Microbiology, Umeå University, SE-901 87 Umeå, Sweden

    5 shared publications
  • Daniel Eklund

    School of Medical Sciences, Faculty of Medicine and Health, Örebro University, SE-701 82 Örebro, Sweden; Inflammatory Response and Infection Susceptibility Centre (iRiSC), Faculty of Medicine and Health, Örebro University, SE-701 82 Örebro, Sweden

    4 shared publications
  • Helén Didriksson

    3 shared publications
  • Maria Lerm

    Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden

    3 shared publications
  • Amanda Welin

    Division of Microbiology and Molecular Medicine, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, SE-58185, Sweden

    2 shared publications

Latest Publications

  • Comparison of High‐Sensitivity Troponin T Versus N‐Terminal Pro‐B‐Type Natriuretic Peptide for Prediction of Major Adverse Cardiovascular Events After Noncardiac Surgery

    by Anna Kirkopoulos, Jan Larmann, Hans‐Joerg Gillmann, René M'PEmbele, Vlad‐Ionut Bucur‐Cristescu, Theresa Tenge, Judith van Waes, Sebastian Roth, Alexandra Stroda‐Hartmann, Henrik Andersson, et al.

    Background: Preoperative hs‐TnT (high‐sensitivity cardiac troponin T) and NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) are used for risk prediction in noncardiac surgery. While the European Society of Cardiology recommends hs‐TnT, American Cardiology and European anesthesiology societies support NT‐proBNP. Direct comparisons of their predictive performance are limited. This study compares preoperative hs‐TnT and NT‐proBNP in predicting cardiac events after noncardiac surgery. Methods: This secondary analysis pooled data from the METREPAIR (Metabolic Equivalents: Reevaluation for Perioperative Cardiac Risk) and MINSS (Myocardial Injury in Noncardiac Surgery in Sweden) studies involving patients with elevated cardiovascular risk undergoing elective noncardiac surgery. The primary end point was the incidence of 30‐day major adverse cardiovascular events, with 30‐day death as the secondary end point. Logistic regression models, including Revised Cardiac Risk Index (RCRI) and age, were augmented by biomarkers. Prediction was assessed using area under the receiver operating characteristic curve, calibration slopes, and Brier scores. Decision curve analysis was conducted at predefined thresholds for major adverse cardiovascular events and death. Results: Among 2251 patients, MACE occurred in 5.8% (131/2251) and death in 1.6% (37/2251). Both biomarkers were significantly associated with outcomes. Only hs‐TnT improved discrimination for predicting death (area under the receiver operating characteristic curve RCRI+age+hsTnT =0.680 versus area under the receiver operating characteristic curve RCRI+age =0.674; Δ area under the curve: 0.006; P =0.047). Brier scores and calibration slopes showed good calibration for all models. Benefit equivalents of RCRI+hs‐TnT versus RCRI+NT‐proBNP were −0.06 per 1000 and −0.17 per 1000 for major adverse cardiovascular events and +0.06 per 1000 versus –0.08 per 1000 (5% threshold) and −0.35 per 1000 versus –0.06 per 1000 (10% threshold) for death. A literature review did not suggest differences between biomarkers. Conclusions: Hs‐TnT and NT‐proBNP were associated with major adverse cardiovascular events and death, but their contribution to risk prediction over RCRI and age was limited. No significant difference was found between biomarkers.

  • Open Access

    Incidence and risk factors for lack of recovery in patients undergoing major abdominal noncardiac surgery in Sweden: a prospective observational study

    by Sara Lyckner, Michelle S. Chew, Anna Neu, Helén Didriksson, Carina Jonsson, Henrik Andersson, Jesper Sperber

  • Open Access

    Physiological and Perceived Stress, Anxiety, Depression and Burnout Among ICU Staff During the COVID‐19 Pandemic in Sweden—An Observational Study

    by Henrik Andersson, Tomas Faresjö, Helén Didriksson, Carina Jonsson, Gunilla Gagnö, Michelle S. Chew

    Purpose: To measure chronic, physiological stress using hair cortisol concentrations (HCC) among ICU staff working during the COVID‐19 pandemic in Sweden, and to evaluate its relationship with perceived stress (PS), anxiety, and depression, and burnout.Materials and Methods: HCC was measured in hair samples of 274 individuals. We tested for differences between females versus males, nurses versus non‐nursing, and ordinary versus deployed staff. PS, anxiety, depression, and burnout were measured using validated questionnaires.Results: Median HCC was 32.6 pg/mg [IQR 21.3–62.3] reflecting physiological stress over 3 months. There were no differences due to sex, profession, and deployment status. Anxiety was detected in 19% and depression in 4% of participants. PS score (23.5 [18.25–29.0]) was higher than previously reported normative data. Burnout was driven by low personal accomplishment. No correlations were found between HCC and PS, anxiety, depression, and burnout.Conclusions: Chronic, physiological stress measured as HCC was not different due to sex, profession or deployment status. Anxiety and burnout were frequent and depression was reported by a minority. HCC did not correlate with PS, anxiety, depression or burnout.


  • Frequency and outcomes of critically ill COVID‐19 patients with tracheostomy, a retrospective two‐center cohort study

    by Louise Elander, Anzal Abdirashid, Henrik Andersson, Jonna Idh, Håkan Johansson, Michelle S. Chew

    Background: The optimal use of tracheostomy in COVID‐19 patients is debated, and considerable uncertainties on the frequency, timing, and outcomes of tracheostomy remain. The objective was to study the frequency and timing of tracheostomy in a real‐world population of critically ill COVID‐19 patients. The secondary aim was to study whether early tracheostomy was associated with days alive and out of intensive care unit (ICU), days free of invasive mechanical ventilation (IMV), 60‐day mortality, ventilator weaning rate, and ICU discharge rate compared to late tracheostomy.Methods: The study is a retrospective two‐center cohort study. All COVID‐19 patients admitted to critical care in the Region Östergötland County Council, Sweden, between March 2020 and September 2021 were included. Early (≤10 days from tracheal intubation) and late (>10 days) tracheostomy were compared. Through the Swedish intensive care registry, 249 mechanically ventilated COVID‐19‐positive patients ≥18 years old with respiratory failure were included. The pre‐defined primary outcomes were the frequency and timing of tracheostomy. Secondary outcomes were days free of mechanical ventilation and intensive care, ICU discharge rate, ventilator weaning rate, and 60‐day mortality.Results: Of 319 identified patients (70% men), 249 (78%) underwent endotracheal intubation. Of these, 145 (58%) underwent tracheostomy and 99 (68%) were performed early. Tracheostomy patients (vs. non‐tracheostomy) had fewer IMV‐free days and ICU‐free days (27 [0–43] vs. 52 [43–55], p < .001, and 24 [0–40] vs. 49 [41–52], p < .001). Late (vs. early) tracheostomy patients had fewer IMV‐ and ICU‐free days (16 [0–31] vs. 36 [0–47], p < .001 and 8 [0–28] vs. 32 [0–44], p < .001). Early tracheostomy (vs. late) was associated with a significantly higher ICU discharge rate (adjusted HR = 0.59, 95% CI [0.40–0.86], p = .006), but not with the weaning rate (adjusted HR = 0.64, 95% CI [0.12–3.32], p = .5) or 60‐day mortality (adjusted HR = 1.27, 95% CI [0.61–2.67], p = .5).Conclusions: Tracheostomy is common in critically ill COVID‐19 patients. In patients predicted to need a tracheostomy at some point, early, rather than late, tracheostomy might be a means to reduce the time spent in ICU. However, we do not have sufficient evidence to suggest that early tracheostomy reduces mortality or weaning rates, compared with late tracheostomy.


  • Effect of perioperative blood transfusion on preoperative haemoglobin levels as a risk factor for long-term outcomes in patients undergoing major noncardiac surgery: a prospective multicentre observational study

    by Fraser J.D. Morris, Rasmus Åhman, Alison Craswell, Helén Didriksson, Carina Jonsson, Manda Gisselgård, Henrik A. Andersson, Yoke-Lin Fung, Michelle S. Chew


  • Open Access

    The Olfactomedin-4-Defined Human Neutrophil Subsets Differ in Proteomic Profile in Healthy Individuals and Patients with Septic Shock

    by Hans Lundquist, Henrik Andersson, Michelle S. Chew, Jyotirmoy Das, Maria V. Turkina, Amanda Welin

    The specific granule glycoprotein olfactomedin-4 (Olfm4) marks a subset (1–70%) of human neutrophils and the Olfm4-high (Olfm4-H) proportion has been found to correlate with septic shock severity. The aim of this study was to decipher proteomic differences between the subsets in healthy individuals, hypothesizing that Olfm4-H neutrophils have a proteomic profile distinct from that of Olfm4 low (Olfm4-L) neutrophils. We then extended the investigation to septic shock. A novel protocol for the preparation of fixed, antibody-stained, and sorted neutrophils for LC-MS/MS was developed. In healthy individuals, 39 proteins showed increased abundance in Olfm4-H, including the small GTPases Rab3d and Rab11a. In Olfm4-L, 52 proteins including neutrophil defensin alpha 4, CXCR1, Rab3a, and S100-A7 were more abundant. The data suggest differences in important neutrophil proteins that might impact immunological processes. However, in vitro experiments revealed no apparent difference in the ability to control bacteria nor produce oxygen radicals. In subsets isolated from patients with septic shock, 24 proteins including cytochrome b-245 chaperone 1 had significantly higher abundance in Olfm4-H and 30 in Olfm4-L, including Fc receptor proteins. There was no correlation between Olfm4-H proportion and septic shock severity, but plasma Olfm4 concentration was elevated in septic shock. Thus, the Olfm4-H and Olfm4-L neutrophils have different proteomic profiles, but there was no evident functional significance of the differences in septic shock.


  • Open Access

    Characteristics and outcomes of patients admitted to Swedish intensive care units for COVID-19 during the first 60 days of the 2020 pandemic: a registry-based, multicenter, observational study

    by Michelle S Chew, Patrik Blixt, Rasmus Åhman, Lars Engerström, Henrik Andersson, Ritva Kiiski Berggren, Anders Tegnell, Sarah McIntyre

    Background: The mortality of patients admitted to the intensive care unit (ICU) with COVID-19 is unclear due to variable censoring and substantial proportions of undischarged patients at follow-up. Nationwide data have not been previously reported. We studied the outcomes of Swedish patients at 30 days after ICU admission. Methods: We conducted a registry-based cohort study of all adult patients admitted to Swedish ICUs from 6 March-6 May, 2020 with laboratory confirmed COVID-19 disease and complete 30-day follow-up. Data including baseline characteristics, comorbidities, intensive care treatments, organ failures and outcomes were collected. The primary outcome was 30-day all-cause mortality. A multivariable model was used to determine the independent association between potential predictor variables and the primary outcome. Results: A total of 1563 patients were identified. Median ICU length of stay was 12 (5-21) days, and fifteen patients remained in ICU at the time of follow-up. Median age was 61 (52-69), median Simplified Acute Physiology Score III (SAPS III) was 53 (46-59), and 66·8% had at least one comorbidity. Median PaO 2 /FiO 2 on admission was 97·5 (75·0-140·6) mmHg, 74·7% suffered from moderate to severe acute respiratory distress syndrome (ARDS). The 30-day all-cause mortality was 26·7%. The majority of deaths occurred during ICU admission. Age, male sex (adjusted odds ratio [aOR] 1·5 [1·1-2·1]), SAPS III score (aOR 1·3 [1·2-1·4]), severe ARDS (aOR 3·1 [2·0-4·8], specific COVID-19 pharmacotherapy (aOR 1·4 [1·0-1·9]), and CRRT (aOR 2·2 [1·6-3·0]), were associated with increased mortality. With the exception of chronic lung disease, the presence of comorbidities was not independently associated with mortality. Conclusions: Thirty-day mortality rate in COVID-19 patients admitted to Swedish intensive care units is generally lower than previously reported. Mortality appears to be driven by age, baseline disease severity, the degree of organ failure and ICU treatment, rather than preexisting comorbidities. Funding: Region Östergötland County Council and Linköping University; number 30320008. Research in context: Evidence before this study: In previous studies reporting outcomes for COVID-19 patients admitted to intensive care units (ICUs), none reported 30-day mortality rates, many were censored after short observation periods, and most had substantial proportions of undischarged patients at the time of follow-up. Incomplete data may cause bias in reported mortality rates. Further, national data on critically ill patients have not been previously published. Added value of this study: Our study provides complete 30-day follow up in a nationwide population of 1563 unselected patients admitted to intensive care units in Sweden. All but 15 patients had been discharged from ICU at follow-up thus the study also provides an accurate reflection of ICU mortality. We also provide age-stratified mortality rates and information on ICU treatment and outcomes. This cohort also differs from previous studies in so far as directed antiviral therapy for COVID-19 disease was infrequently used. Adjusted risk estimates for the effect of baseline factors, ICU complications and treatment demonstrate that age, the severity of respiratory failure and need for continuous renal replacement therapy were the most important risk factors for death. Implications of all the available evidence: Mortality rates of COVID-19 patients in Swedish ICUs are lower than those previously reported, despite the high incidence of comorbidities, an ageing population and a high proportion of patients with severe ARDS. Directed antiviral pharmacotherapy was given only to a minority of patients suggesting that survival from COVID-19 in ICU is achievable with good supportive care. Our analysis also suggests that unaccounted factors eg. process and organizational, may be important in determining the outcome of critically ill patients with COVID-19. Our results may be of interest since Sweden has a very limited number of ICU beds and has adopted a unique response to the pandemic compared to other countries. Despite limited numbers of ICU beds per capita, Sweden was able to increase its ICU capacity during the first 2 months of the COVID-19 pandemic and provide essential care to the critically ill with encouraging results.


  • Myocardial injury in noncardiac surgery in Sweden

    by Johan Snygg, Henrik Andersson, Mats Fredrikson, Michelle S. Chew

  • Open Access

    Macrophage traits in cancer cells are induced by macrophage-cancer cell fusion and cannot be explained by cellular interaction

    by Ivan Shabo, Kristine Midtbö, Henrik Andersson, Emma Åkerlund, Hans Olsson, Pia Wegman, Cecilia Gunnarsson, Annelie Lindström

    Cell fusion is a natural process in normal development and tissue regeneration. Fusion between cancer cells and macrophages generates metastatic hybrids with genetic and phenotypic characteristics from both maternal cells. However, there are no clinical markers for detecting cell fusion in clinical context. Macrophage-specific antigen CD163 expression in tumor cells is reported in breast and colorectal cancers and proposed being caused by macrophages-cancer cell fusion in tumor stroma. The purpose of this study is to examine the cell fusion process as a biological explanation for macrophage phenotype in breast. Monocytes, harvested from male blood donor, were activated to M2 macrophages and co-cultured in ThinCert transwell system with GFP-labeled MCF-7 cancer cells. MCF7/macrophage hybrids were generated by spontaneous cell fusion, isolated by fluorescence-activated cell sorting and confirmed by fluorescence microscopy, short tandem repeats analysis and flow cytometry. CD163 expression was evaluated in breast tumor samples material from 127 women by immunohistochemistry. MCF-7/macrophage hybrids were generated spontaneously at average rate of 2 % and showed phenotypic and genetic traits from both maternal cells. CD163 expression in MCF-7 cells could not be induced by paracrine interaction with M2-activated macrophages. CD163 positive cancer cells in tumor sections grew in clonal collection and a cutoff point >25 % of positive cancer cells was significantly correlated to disease free and overall survival. In conclusion, macrophage traits in breast cancer might be caused by cell fusion rather than explained by paracrine cellular interaction. These data provide new insights into the role of cell fusion in breast cancer and contributes to the development of clinical markers to identify cell fusion.


  • Orexin a phosphorylates the γ‐Aminobutyric acid type A receptor β2 subunit on a serine residue and changes the surface expression of the receptor in SH‐SY5Y cells exposed to propofol

    by Henrik Andersson, Karin Björnström, Christina Eintrei, Tommy Sundqvist

    Propofol activates the γ-aminobutyric acid type A receptor (GABAAR) and causes a reversible neurite retraction, leaving a thin, thread-like structure behind; it also reverses the transport of vesicles in rat cortical neurons. The awakening peptide orexin A (OA) inhibits this retraction via phospholipase D (PLD) and protein kinase Cɛ (PKCɛ). The human SH-SY5Y cells express both GABAARs and orexin 1 and 2 receptors. These cells are used to examine the interaction between OA and the GABAAR. The effects of OA are studied with flow cytometry and immunoblotting. This study shows that OA stimulates phosphorylation on the serine residues of the GABAAR β2 subunit and that the phosphorylation is caused by the activation of PLD and PKCɛ. OA administration followed by propofol reduces the cell surface expression of the GABAAR, whereas propofol stimulation before OA increases the surface expression. The GABAAR β2 subunit is important for receptor recirculation, and the effect of OA on propofol-stimulated cells may be due to a disturbed recirculation of the GABAAR.